Related Experiment Video
Updated: Jul 24, 2025
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.4K
Minimum data elements for the Australian Particle Therapy Clinical Quality Registry.
Eunji Hwang1,2, Peter Gorayski3,4,5, David Thwaites2
1Department of Radiation Oncology, Sydney West Radiation Oncology Network, Sydney, New South Wales, Australia.
Journal of Medical Imaging and Radiation Oncology
|July 7, 2023
Summary
A consensus identified 27 essential Minimum Data Elements (MDEs) for Australia's national particle therapy (PT) registry, ASPIRE. This registry is crucial for collecting data on PT patient and tumor outcomes.
Area of Science:
- Oncology
- Medical Physics
- Health Informatics
Background:
- Australia is establishing its first particle therapy (PT) center.
- A national registry, the Australian Particle Therapy Clinical Quality Registry (ASPIRE), is mandated for PT reimbursement.
- This study aimed to define the core data for ASPIRE.
Purpose of the Study:
- To establish a consensus set of Minimum Data Elements (MDEs) for the Australian national particle therapy registry (ASPIRE).
- To ensure comprehensive data collection for quality assurance and clinical evidence development in particle therapy.
Main Methods:
- A modified Delphi and expert consensus process was employed.
- International PT registries were reviewed to identify common MDEs.
- A three-round process involving surveys, polls, and expert discussions refined the MDEs.
Main Results:
- 123 unique MDEs were identified across four international registries.
- A consensus process resulted in 27 essential MDEs for ASPIRE.
- These include 14 patient factors, 4 tumor factors, and 9 treatment factors.
Conclusions:
- The 27 MDEs form the mandatory core data for the ASPIRE registry.
- Registry data is vital for building robust clinical evidence on PT outcomes.
- This evidence will support the clinical benefit and cost-effectiveness of PT.
